TriSalus Life Sciences (NASDAQ:TLSI) Releases Quarterly Earnings Results, Misses Estimates By $0.08 EPS

TriSalus Life Sciences (NASDAQ:TLSI) issued its quarterly earnings results on Thursday. The company reported ($0.21) earnings per share for the quarter, missing the consensus estimate of ($0.13) by ($0.08), FiscalAI reports. The company had revenue of $13.21 million during the quarter, compared to the consensus estimate of $13.20 million.

TriSalus Life Sciences Stock Performance

Shares of NASDAQ:TLSI traded down $0.23 during midday trading on Thursday, reaching $4.77. 247,625 shares of the company’s stock traded hands, compared to its average volume of 158,661. The company has a market cap of $238.79 million, a price-to-earnings ratio of -2.36 and a beta of 0.42. TriSalus Life Sciences has a one year low of $3.42 and a one year high of $7.95. The stock has a 50 day moving average of $5.46 and a 200 day moving average of $5.36.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on TLSI. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of TriSalus Life Sciences in a research report on Monday, December 29th. Zacks Research raised shares of TriSalus Life Sciences from a “strong sell” rating to a “hold” rating in a research note on Tuesday, December 16th. Wall Street Zen cut TriSalus Life Sciences from a “hold” rating to a “sell” rating in a research report on Sunday, February 8th. Finally, Canaccord Genuity Group lifted their price objective on TriSalus Life Sciences from $11.00 to $12.00 and gave the company a “buy” rating in a research note on Wednesday, December 17th. One research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, TriSalus Life Sciences currently has an average rating of “Hold” and an average target price of $12.00.

Hedge Funds Weigh In On TriSalus Life Sciences

Hedge funds and other institutional investors have recently modified their holdings of the company. Goldman Sachs Group Inc. bought a new stake in shares of TriSalus Life Sciences in the first quarter worth $187,000. Geode Capital Management LLC grew its stake in shares of TriSalus Life Sciences by 107.4% during the 2nd quarter. Geode Capital Management LLC now owns 455,051 shares of the company’s stock valued at $2,480,000 after purchasing an additional 235,627 shares during the period. JPMorgan Chase & Co. increased its position in shares of TriSalus Life Sciences by 35,804.8% during the 2nd quarter. JPMorgan Chase & Co. now owns 7,540 shares of the company’s stock valued at $41,000 after purchasing an additional 7,519 shares during the last quarter. New York State Common Retirement Fund bought a new position in shares of TriSalus Life Sciences in the 2nd quarter worth approximately $108,000. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new position in shares of TriSalus Life Sciences in the second quarter worth approximately $47,000. 2.58% of the stock is owned by institutional investors.

About TriSalus Life Sciences

TriSalus Life Sciences, Inc is a clinical-stage biotechnology company focused on the development and commercialization of non-invasive drug–device combination therapies for oncology applications. Leveraging proprietary electroporation and ultrasound platforms, the company aims to enhance the localized delivery and efficacy of established chemotherapeutic agents while reducing systemic toxicity. Its lead programs target hard-to-treat head and neck cancers, where improved tumor control and patient tolerability remain significant unmet needs.

The company’s pipeline comprises investigational product candidates in early and mid-stage clinical trials, including studies that combine its electrochemotherapy platform with radiation therapy and immuno-oncology agents.